This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2009 Feb;50(2):154-5.

doi: 10.1080/10428190902717059.

JAK2V617F: more than a clonal marker?

Ayalew Tefferi¹

Affiliations

PMID: 19235012
DOI: 10.1080/10428190902717059

Comment

JAK2V617F: more than a clonal marker?

Ayalew Tefferi. Leuk Lymphoma. 2009 Feb.

. 2009 Feb;50(2):154-5.

doi: 10.1080/10428190902717059.

Author

Ayalew Tefferi¹

Affiliation

¹ Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA. tefferi.ayalew@mayo.edu

PMID: 19235012
DOI: 10.1080/10428190902717059

No abstract available

PubMed Disclaimer

Comment on

JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients.
Palandri F, Ottaviani E, Salmi F, Catani L, Polverelli N, Fiacchini M, Martinelli G, Baccarani M, Vianelli N. Palandri F, et al. Leuk Lymphoma. 2009 Feb;50(2):247-53. doi: 10.1080/10428190802688152. Leuk Lymphoma. 2009. PMID: 19235016

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon